Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diquafosol Sodium for Mild to Moderate MGD
NCT05383612Unknown
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Aug 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of diquafosol in meibomian gland dysfunction (MGD) and dry eye syndrome (DED), sponsored by Zhongshan Ophthalmic Center. Status: unknown.
02
Drugs
diquafosol
03
Conditions
meibomian gland dysfunction (MGD)dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT05383612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383612.